Loading
A phase 1/2 trial of PF-08634404, Ipilimumab in hepatocellular carcinoma, run by Pfizer, now recruiting.
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. is a phase 1/2 interventional study registered as NCT07227012 by Pfizer, with 138 participants planned, started 2025-12-01 and due to reach its primary completion in 2027-10-18. Interventions recorded: PF-08634404, Ipilimumab. Conditions listed: Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PF-08634404, Ipilimumab, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Ipilimumab, Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/